Pyrintegrin
目录号 : GC17607
An enhancer of human ESC survival
Cas No.:1228445-38-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pyrintegrin, a 2,4-disubstituted pyrimidine, is a novel small-molecule inhibitor of BMP signaling which previously found to promote human embryonic stem cells survival [1].
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily of secreted signaling molecules with important roles in many biological contexts. BMPs could bind to specificserine/threonine kinase receptors and transduce the signal to the nucleus through Smad proteins [2].
In vitro: Pyrintegrin induced differentiation of hADSCs into adipogenic‐like cells in vitro. Pyrintegrin drug treatment can accelerate adipocyte differentiation and augment lipid accumulation, adiponectin and fatty acid secretion in adipogenic medium differentiated human adipose derived stem cells [1]. Pyrimidine (2 μM) enhanced the survival of hESC more than 30-fold after trypsin-mediated dissociation. Pyrimidine increased integrin-dependent attachment of hESC to extracellular matrices without significantly impacting cell proliferation. Pyrintegrin increased the binding of the activated β1 integrin-specific antibody HUTS-21 and enhanced the phosphorylation of multiple growth factor receptors and their downstream kinases, PI3K and MAPK [3].
In vivo: Pyrintegrin promoted proliferation and differentiation of adipose precursor cells depending on their microenvironment. Pyrintegrin increased the number of preadipocytes and the rate of adipocyte differentiation, resulting in enhanced de novo adipogenesis [1].
References:
[1] Shah B S. Pyrintegrin Induced Adipogenesis: Biology[D]. Columbia University, 2012.
[2] von Bubnoff A, Cho K W Y. Intracellular BMP signaling regulation in vertebrates: pathway or network[J]. Developmental biology, 2001, 239(1): 1-14.
[3] Xu Y, Zhu X, Hahm H S, et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules[J]. Proceedings of the National Academy of Sciences, 2010, 107(18): 8129-8134.
| Cas No. | 1228445-38-2 | SDF | |
| 化学名 | N-(cyclopropylmethyl)-4-[[4-(3,4-dihydro-6-hydroxy-1(2H)-quinolinyl)-2-pyrimidinyl]amino]-benzenesulfonamide | ||
| Canonical SMILES | OC1=CC2=C(C=C1)N(C3=CC=NC(NC4=CC=C(S(NCC5CC5)(=O)=O)C=C4)=N3)CCC2 | ||
| 分子式 | C23H25N5O3S | 分子量 | 451.5 |
| 溶解度 | ≤1mg/ml in ethanol;30mg/ml in DMSO;50mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2148 mL | 11.0742 mL | 22.1484 mL |
| 5 mM | 0.443 mL | 2.2148 mL | 4.4297 mL |
| 10 mM | 0.2215 mL | 1.1074 mL | 2.2148 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。